NEW YORK (GenomeWeb News) – Celera and Medco Health Solutions will collaborate to study whether patients who take a test for a specific gene variant are more likely to adhere to their treatment regimens for lipid-lowering statins.

Celera said today that it will work with Medco to conduct a prospective, randomized, multi-center study to find out if testing for the KIF6 variant can be a predictor for patient adherence.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.